豚用ワクチンの世界市場

豚用ワクチンの世界市場は2030年までに21億米ドルに達する見込み

2024年に17億米ドルと推定される豚用ワクチンの世界市場は、2024年から2030年にかけてCAGR 3.7%で成長し、2030年には21億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである不活性化は、CAGR4.1％を記録し、分析期間終了までに13億米ドルに達すると予想されます。修正／不活化生菌セグメントの成長率は、分析期間中CAGR 2.7％と推定されます。

米国市場は推定4億6,260万米ドル、中国はCAGR6.9％で成長すると予測

米国の豚用ワクチン市場は、2024年に4億6,260万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR6.9%を牽引し、2030年までに4億2,440万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.8%と予測されています。欧州では、ドイツがCAGR 2.1%で成長すると予測されています。

世界の豚用ワクチン市場- 主要動向と促進要因まとめ

なぜワクチンが現代の豚群管理の中心になりつつあるのか？

世界の養豚業界は、新興感染症やバイオセキュリティの脅威から抗生物質削減への圧力の高まりに至るまで、様々な課題に直面しています。このような状況の中で、ワクチンは予防的な選択肢から、牛群の健康戦略の基礎となる要素へと進化してきました。アフリカ豚熱（ASF）、豚繁殖・呼吸器症候群（PRRS）、古典的豚熱（CSF）といった疾病が発生し、主要な豚肉生産地域全体で壊滅的な損失をもたらしているため、生産者はリスクを軽減し、生産の継続性を守るために、ワクチン接種プロトコルにますます依存するようになっています。ワクチンは風土病の抑制に役立つだけでなく、二次感染の発生率を低下させ、抗菌薬の全体的な使用量を減らすことができます。さらに、養豚の規模と密度が高まるにつれて、急速な疾病伝播の脅威が増大し、罹患率と死亡率を最小限に抑えるために定期的な予防接種が不可欠となっています。その結果、ワクチン接種はもはやコストとはみなされず、むしろ牛群の回復力、生産性、長期的な収益性を高めるための投資とみなされ、世界的に豚の健康管理の中核を担っています。

新しいワクチン技術は豚の疾病予防をどのように変えているのか？

技術革新は、豚用ワクチンの開発と提供を再構築し、より迅速で、より効果的で、より的を絞った予防接種戦略を可能にしています。組換えDNA技術、ウイルスベクタープラットフォーム、RNAベースのワクチンの進歩は、より少ない副作用でより広い予防効果を提供する次世代ソリューションへの道を開いています。マーカー（DIVA）ワクチン-感染動物とワクチン接種動物を区別するワクチン-は、無病の認証を維持しながらサーベイランスをサポートするため、特にCSFのような貿易に影響する疾病で注目されています。さらに、ワクチン接種スケジュールを簡素化し、投与中の動物のストレスを軽減するために、多価ワクチンや混合ワクチンが開発されています。皮内投与や針を使用しない送達システムは、組織損傷や交差汚染のリスクを最小限に抑えることで、動物福祉とバイオセキュリティの両方を向上させています。診断連動型ワクチン接種（DLV）システムも試験的に導入されており、リアルタイムの疾病診断とワクチン接種の決定を統合することで、接種のタイミングと効果を向上させています。これらの技術革新は、生産者が牛群全体でより高い免疫レベルを達成し、労働時間を削減し、ワクチン接種プログラムを進化する疾病圧力に合わせて調整するのに役立っています。

規制、貿易力学、バイオセキュリティの義務はどのような役割を果たすのか？

豚用ワクチン市場は、規制の枠組み、国際貿易の状況、進化するバイオセキュリティの義務付けに深く影響されています。多くの国では、ワクチンの使用はUSDA、EMA、CFDAなどの政府当局によって厳しく規制されており、安全性、有効性、コンプライアンスを確保するために厳格な承認経路が設けられています。豚肉の世界貿易が、特にアジア、欧州、南北アメリカ間で拡大し続ける中、疾病管理は輸出適格性の必須条件となっています。効果的なワクチン接種プログラムと無病状態を証明できる国は、市場アクセスや貿易パートナーシップを維持する上で大きな優位性を持っています。このため政府は、特にASFや口蹄疫（FMD）のような届出可能で国境を越える疾病に対して、大規模なワクチン接種キャンペーンに資金を提供するようになりました。さらに、業界主導の認証や小売業者の調達要件は、動物福祉や持続可能性への取り組みの一環として、包括的なワクチン接種記録を維持するよう生産者に促しています。バイオセキュリティーは養豚の中心的な考え方となっており、特に最近のアウトブレイクを踏まえ、ワクチンは総合的な疾病予防プロトコルの中で、第一の防御ラインとみなされるようになっています。規制、貿易、農場レベルの期待が一致することで、最新の養豚生産における防御手段とコンプライアンス要件の両方として、ワクチン導入が強化されています。

豚用ワクチン市場の力強い成長の原動力は？

豚用ワクチン市場の成長は、疫学的動向、技術の進歩、生産システムの進化、世界の政策調整など、さまざまな要因が重なり合うことによってもたらされます。PRRS、肺炎マイコプラズマ、ASFといった感染症や新興疾病の流行の高まりは、予防用ワクチンと緊急用ワクチンの両方に対する持続的な需要を生み出しています。アジュバント製剤、抗原探索、ワクチンデリバリーにおける技術の進歩は、製品の入手可能性と有効性を拡大し、技術革新のための新たな分野を開発しています。規制の禁止、輸出基準、消費者の意識に後押しされた抗生物質からの世界のシフトは、主要な疾病管理戦略としてのワクチンの重要性を高めています。生産レベルでは、養豚の強化と大規模経営の統合により、牛群の健康管理の経済的価値が高まっており、ワクチンはリスク軽減の中心的役割を担っています。これと並行して、アジア、ラテンアメリカ、アフリカでは、官民パートナーシップや政府が資金を提供する予防接種イニシアチブが、商業系と零細農家の両方へのワクチン導入を支援しています。コールドチェーン・ロジスティクスの改善、獣医療情報学の台頭、精密畜産プラットフォームへのワクチン接種の統合は、アクセシビリティとインパクトをさらに高めています。こうした市場促進要因が相まって、豚用ワクチン市場は前進し、持続可能でスケーラブル、かつ生物学的に安全な豚肉生産の重要な柱としての地位を世界中で確固たるものにしています。

セグメント

製品タイプ（不活化、弱毒化、その他）、疾病タイプ（豚インフルエンザ、豚熱、豚パルボウイルス、豚サーコウイルス2型、M.Hyo、アクチノバチルス肺炎、PRRS、口蹄疫、狂犬病、PEDV、その他）、投与経路（注射剤、経鼻剤、経口剤）

調査対象企業の例

• Aptimmune Biologics
• Baseimmune
• Biogenesis Bago
• Boehringer Ingelheim International GmbH
• Cambridge Technologies
• Ceva Sante Animale
• Codagenix
• Elanco Animal Health Incorporated
• Genvax Technologies
• HIPRA
• Indian Immunologicals Limited
• iBio
• KM Biologics
• Merck & Co., Inc.
• Phibro Animal Health Corporation
• Ring Biotechnology Co Ltd.
• Sequent Scientific Limited
• Serum Institute of India
• Vaxxinova International BV
• Vetoquinol S.A.
• Virbac
• ViroVet

AI統合

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Swine Vaccines Market to Reach US$2.1 Billion by 2030

The global market for Swine Vaccines estimated at US$1.7 Billion in the year 2024, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Inactivated, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Modified / Attenuated Live segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$462.6 Million While China is Forecast to Grow at 6.9% CAGR

The Swine Vaccines market in the U.S. is estimated at US$462.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$424.4 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Swine Vaccines Market - Key Trends & Drivers Summarized

Why Are Vaccines Becoming Central to Modern Swine Herd Management?

The global swine industry is confronting mounting challenges ranging from emerging infectious diseases and biosecurity threats to growing pressure for antibiotic reduction. In this context, vaccines have evolved from a preventive option to a foundational component of herd health strategies. With disease outbreaks like African Swine Fever (ASF), Porcine Reproductive and Respiratory Syndrome (PRRS), and Classical Swine Fever (CSF) causing devastating losses across major pork-producing regions, producers are increasingly leaning on vaccination protocols to mitigate risks and protect production continuity. Vaccines not only help control endemic diseases but also reduce the incidence of secondary infections, lowering the overall use of antimicrobials-a key goal in the global fight against antimicrobial resistance (AMR). Moreover, as pig farming scales up in intensity and density, the threat of rapid disease transmission grows, making routine immunization essential to minimize morbidity and mortality. As a result, vaccination is no longer seen as a cost but rather an investment in herd resilience, productivity, and long-term profitability, securing its place at the core of swine health management worldwide.

How Are New Vaccine Technologies Transforming Swine Disease Prevention?

Technological innovation is reshaping the development and delivery of swine vaccines, enabling faster, more effective, and more targeted immunization strategies. Advances in recombinant DNA technologies, viral vector platforms, and RNA-based vaccines are paving the way for next-generation solutions that offer broader protection with fewer side effects. Marker (DIVA) vaccines-those that differentiate infected from vaccinated animals-are gaining prominence, particularly for diseases with trade implications like CSF, as they support surveillance while maintaining disease-free certifications. Additionally, multivalent and combination vaccines are being developed to simplify vaccination schedules and reduce animal stress during administration. Intradermal and needle-free delivery systems are improving both animal welfare and biosecurity by minimizing tissue damage and cross-contamination risks. Diagnostic-linked vaccination (DLV) systems are also being piloted, integrating real-time disease diagnostics with vaccination decisions to improve timing and efficacy. These innovations are helping producers achieve higher immunity levels across herds, reduce labor time, and tailor vaccination programs to evolving disease pressures-marking a new era in data-driven, precision veterinary medicine.

What Role Do Regulations, Trade Dynamics, and Biosecurity Mandates Play?

The swine vaccines market is deeply influenced by regulatory frameworks, international trade conditions, and evolving biosecurity mandates. In many countries, vaccine use is closely regulated by government authorities such as the USDA, EMA, or CFDA, with strict approval pathways to ensure safety, efficacy, and compliance. As global pork trade continues to grow, especially between Asia, Europe, and the Americas, disease control becomes a prerequisite for export eligibility. Countries that can demonstrate effective vaccination programs and disease-free status have a significant advantage in maintaining market access and trade partnerships. This has pushed governments to fund mass vaccination campaigns, particularly for notifiable and transboundary diseases like ASF and Foot-and-Mouth Disease (FMD). Additionally, industry-driven certifications and retailer sourcing requirements are encouraging producers to maintain comprehensive vaccination records as part of animal welfare and sustainability commitments. Biosecurity has become a central tenet in swine farming, especially in light of recent outbreaks, and vaccines are now viewed as the first line of defense within integrated disease prevention protocols. The alignment of regulatory, trade, and farm-level expectations is reinforcing vaccine adoption as both a protective measure and a compliance requirement in modern swine production.

What’s Driving the Strong Growth in the Swine Vaccines Market?

The growth in the swine vaccines market is driven by a confluence of factors that span epidemiological trends, technological advancement, production system evolution, and global policy alignment. The rising prevalence of infectious and emerging diseases-such as PRRS, Mycoplasma hyopneumoniae, and ASF-is creating sustained demand for both prophylactic and emergency-use vaccines. Technological progress in adjuvant formulations, antigen discovery, and vaccine delivery is broadening product availability and effectiveness, opening up new segments for innovation. The global shift away from antibiotics-driven by regulatory bans, export standards, and consumer awareness-is amplifying the importance of vaccines as a primary disease control strategy. At the production level, intensification of swine farming and the consolidation of large-scale operations are increasing the economic value of herd health management, with vaccines playing a central role in risk mitigation. In parallel, public-private partnerships and government-funded immunization initiatives in Asia, Latin America, and Africa are supporting vaccine deployment in both commercial and smallholder systems. Improved cold chain logistics, the rise of veterinary health informatics, and the integration of vaccination into precision livestock farming platforms are further enhancing accessibility and impact. Together, these drivers are propelling the swine vaccines market forward-solidifying its position as a critical pillar of sustainable, scalable, and biosecure pork production worldwide.

SCOPE OF STUDY:

The report analyzes the Swine Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Inactivated, Modified / Attenuated Live, Others); Disease Type (Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo, Actinobacillus Pleuropneumonia, PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Others); Administration Route (Injectables, Intranasal, Oral)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Aptimmune Biologics
• Baseimmune
• Biogenesis Bago
• Boehringer Ingelheim International GmbH
• Cambridge Technologies
• Ceva Sante Animale
• Codagenix
• Elanco Animal Health Incorporated
• Genvax Technologies
• HIPRA
• Indian Immunologicals Limited
• iBio
• KM Biologics
• Merck & Co., Inc.
• Phibro Animal Health Corporation
• Ring Biotechnology Co Ltd.
• Sequent Scientific Limited
• Serum Institute of India
• Vaxxinova International BV
• Vetoquinol S.A.
• Virbac
• ViroVet

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Swine Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Endemic and Emerging Swine Diseases Throws the Spotlight on Prophylactic Vaccination Strategies
  • Growing Concerns Over Antibiotic Resistance Strengthen the Business Case for Preventive Vaccination in Swine Herds
  • Expansion of Intensive Pig Farming Operations Propels Demand for Scalable and Efficient Vaccine Protocols
  • Increased Awareness of Zoonotic Disease Risks Drives Adoption of Biosecurity-Linked Vaccination Programs
  • Technological Advancements in Vaccine Formulation and Delivery Generate Demand for Next-Generation Swine Vaccines
  • Integration of Precision Livestock Tools with Veterinary Protocols Accelerates Demand for Data-Driven Vaccination Management
  • Surge in Global Pork Consumption Expands the Addressable Market for Herd Immunization Solutions
  • Emergence of Novel Pathogen Strains and Mutations Creates Ongoing Challenges for Vaccine Efficacy and Coverage
  • Government-Led Mass Vaccination Programs and Subsidies Sustain Growth in Developing and Disease-Prone Regions
  • Digital Health Monitoring and Traceability Systems Enhance Compliance with Vaccination Schedules and Records
  • Rising Demand for Customized and Region-Specific Vaccines Drives Collaboration Between Biotech Firms and Local Producers
  • Improvements in Cold Chain Infrastructure and Logistics Facilitate Wider Access to Thermo-Sensitive Vaccine Products
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Swine Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Swine Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Swine Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Swine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Modified / Attenuated Live by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Modified / Attenuated Live by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Modified / Attenuated Live by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for PRRS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for PRRS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for PRRS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Foot & Mouth Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Foot & Mouth Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Foot & Mouth Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Pseudorabies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Pseudorabies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Pseudorabies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for PEDV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for PEDV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for PEDV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Swine Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Swine Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Swine Influenza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Classical Swine Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Classical Swine Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Classical Swine Fever by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Porcine Parvovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Porcine Parvovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Porcine Parvovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Porcine Circovirus Type 2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Porcine Circovirus Type 2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Porcine Circovirus Type 2 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for M.Hyo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for M.Hyo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for M.Hyo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Actinobacillus Pleuropneumonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Actinobacillus Pleuropneumonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Actinobacillus Pleuropneumonia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Intranasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Intranasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Intranasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 56: USA Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• JAPAN
  • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• CHINA
  • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 83: China Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• EUROPE
  • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Swine Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Swine Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Swine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• FRANCE
  • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 104: France Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• GERMANY
  • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 131: UK Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 134: UK Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: UK Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: UK 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 137: UK Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: UK Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: UK 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 143: Spain Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Spain Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Spain 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 146: Spain Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Spain Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Spain 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 152: Russia Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Russia Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Russia 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 155: Russia Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Russia Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Russia 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Europe Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Rest of Europe 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Europe Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Rest of Europe 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Swine Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Swine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Asia-Pacific Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Asia-Pacific 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Asia-Pacific Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Asia-Pacific 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 182: Australia Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Australia Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Australia 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 185: Australia Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Australia Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Australia 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• INDIA
  • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 188: India Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 191: India Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: India Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: India 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 194: India Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: India Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: India 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 200: South Korea Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: South Korea Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: South Korea 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 203: South Korea Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: South Korea Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: South Korea 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Asia-Pacific Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Asia-Pacific 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Rest of Asia-Pacific Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Rest of Asia-Pacific 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Swine Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Swine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 221: Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Latin America Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Latin America 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 224: Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Latin America Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Latin America 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 230: Argentina Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Argentina Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Argentina 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 233: Argentina Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Argentina Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Argentina 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 239: Brazil Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Brazil Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Brazil 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 242: Brazil Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Brazil Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Brazil 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 248: Mexico Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Mexico Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Mexico 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 251: Mexico Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Mexico Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Mexico 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Latin America Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Latin America 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Latin America Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Latin America 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Swine Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Swine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 269: Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Middle East Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Middle East 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 272: Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Middle East Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Middle East 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 278: Iran Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Iran Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Iran 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 281: Iran Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Iran Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Iran 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 287: Israel Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Israel Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Israel 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 290: Israel Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Israel Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Israel 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Saudi Arabia Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Saudi Arabia 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Saudi Arabia Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Saudi Arabia 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 305: UAE Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: UAE Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: UAE 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 308: UAE Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: UAE Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: UAE 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Middle East Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Middle East 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Middle East Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Middle East 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
• AFRICA
  • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
  • TABLE 323: Africa Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Africa Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Africa 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
  • TABLE 326: Africa Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Africa Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Africa 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030

IV. COMPETITION